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Objective: Prospective memory (PM), that is, the ability to keep in memory and carry
out intentions in the future, is reported to be impaired in individuals with Parkinson’s
disease (PD). PM failure may be also associated with reduced daily living functioning in
these patients. Little is known, however, about the relationship between mild cognitive
impairment (MCI) and time-based PM functioning in PD patients and the possible impact
of PM deficits on patients’ autonomy in daily living. Here we aimed to investigate whether
MCI associated with PD affects time-based PM. We also wished to determine whether
PM impairment accounts for reduced autonomous management of medication in these
patients.
Method: The study included 48 PD patients with MCI, 33 PD patients without cognitive
disorders (PDN) and 20 healthy controls. The time-based PM procedure required that
subjects perform an action after a fixed time. The PM procedure was incorporated in the
standard neuropsychological assessment. One score was computed for the ability to
retrieve the intention (prospective component) and one for remembering the action to be
executed (retrospective component). The Pill Questionnaire was administered to assess
the ability to manage medication.
Results: PD patients with MCI performed less accurately in the PM procedure than HC
and tended to perform poorer than PDN. Moreover, in PD patients with MCI, accuracy
on the prospective component of the PM task and performance on the Modified Card
Sorting Test significantly predicted the ability to manage medication.
Conclusions: Results document that reduced efficiency of time-based PM processes
in PD is specifically related to the presence of MCI. The same data indicate that
PM weakness may be associated with impaired daily living functioning and decreased
autonomy.
Keywords: prospective memory, Parkinson’s disease, medication management, cognitive functions, daily living
Frontiers in Human Neuroscience | www.frontiersin.org 1 June 2015 | Volume 9 | Article 333
Costa et al. Prospective memory in Parkinson’s disease
Introduction
Prospective memory (PM), that is, the ability to keep in mind
and carry out future intentions, is consistently impaired in
individuals with Parkinson’s disease (PD). In fact, studies using
both event-based paradigms, which require subjects to execute
a delayed action at the occurrence of an environmental cue,
and time-based tasks, which require subjects to execute a
delayed action at the expiration of a certain time, document
that PD patients perform significantly worse than healthy
controls (Kliegel et al., 2011; Costa et al., 2013a; Foster
et al., 2013). There is also evidence that in this population
PM impairment is related to dysexecutive symptoms (Kliegel
et al., 2011; Costa et al., 2014) and a role has been suggested
for the dysfunctioning of dopamine systems (Costa et al.,
2008a).
Findings of a recent study also raised the question of whether
PM weakness is tout-court related to PD in PD patients or
whether it is the expression of cognitive impairment (Costa et al.,
2015a). In particular, in that study PD patients with and without
mild cognitive impairment (MCI) and healthy controls were
administered an event-based task in focal (the PM target was
processed in the ongoing task) and non-focal (the PM target
was not processed during the ongoing task) conditions. Results
documented that PD patients with MCI performed worse than
both healthy controls and PD patients without MCI, who in
turn performed comparably (Costa et al., 2015a). These findings
have clinical relevance because they suggest that PM disorders
may be a specific sign of MCI associated with PD. Indeed,
as outlined by several authors MCI can be considered as a
prodromal condition of different neurological syndromes with
dementia (Petersen et al., 2001; Dubois et al., 2007a, 2010;
Cummings et al., 2013). An elevated risk of dementia has
also been reported for individuals with MCI associated with
PD compared to individuals with PD without MCI (Litvan
et al., 2012; Halliday et al., 2014). Therefore, clarifying whether
PM impairments depend on MCI in PD is an important
issue that could provide useful information for diagnosis and
treatment.
Another open question concerns the possible relationship
between PD patients’ PM weakness and reduced ability to self-
manage daily living commitments. Indeed, PM impairment is
reported to significantly affect functional activities in persons
with various neurological diseases (Kinsella et al., 1996; Burgess
et al., 2000; Schmitter-Edgecombe et al., 2009; Fish et al., 2010;
Kliegel et al., 2011). In PD patients, Pirogovsky et al. (2012) found
that decreased PM efficiency, as assessed by both self-report
and performance-based tools, was significantly associated with
reduced ability to successfully manage their own medication. In
a recent investigation this relationship was also described in PD
patients with MCI. In particular, in a sample of PD patients
with single-domain and multiple-domain MCI event-based PM
scores were found to significantly predict scores on the Pill
questionnaire, a tool aimed at ascertaining whether PD patients
are able to autonomously manage pharmacological therapy
(Costa et al., 2015a). This was the first study directly aimed
at exploring this issue, which is undoubtedly worthy of further
investigation. Moreover, the possible effect of other factors such
as depression, apathy and severity of extrapiramidal symptoms,
whichmight significantly affect daily livingmanagement, was not
taken into account.
To the best of our knowledge, time-based PM functioning
has never been compared in PD patients with and without MCI.
Moreover, its relationship with self-management of daily living
commitments has never been investigated in individuals with
MCI associated with PD. Therefore, this study was specifically
aimed at investigating these issues. For this purpose, we
administered a time-based PM procedure that was incorporated
in the standard neuropsychological examination to two groups
of PD patients with single- and multiple-domain MCI, a group
of PD patients without MCI and a group of healthy controls.
Based on previous data concerning event-based PM functioning,
we predicted that PD patients with MCI, but not PD patients
without MCI, would obtain lower PM scores than healthy
controls.
To comply with the second aim of study, that is, to investigate
the relationship between PD patients’ PM performance and their
autonomy in daily living, a regression model was applied to the
data. In particular, we evaluated the relative contribution of PM
scores to the score variability on the Pill questionnaire (Dubois
et al., 2007b), taking into account the weight of other relevant
cognitive (i.e., global cognitive functioning, episodic memory
and executive abilities), affective (i.e., depression and apathy)
and motor (severity of extrapiramidal symptoms) variables.
According to previous evidence of an association between
PM failure and reduced daily living functioning also in PD
patients (Pirogovsky et al., 2012; Costa et al., 2015a), we
expected that PM performance would predict the ability of
PD patients with MCI to autonomously manage their own
medication.
Materials and Methods
Participants
We recruited 81 right-handed individuals with idiopathic PD
and 20 right-handed healthy controls (HC; F = 17; M = 3);
they participated in the study after giving their written informed
consent. The study was approved by the Ethics Committee of
Fondazione Santa Lucia.
Idiopathic PD was defined according to the United Kingdom
PD Society brain bank criteria (Hughes et al., 1992). Diagnosis
of MCI was made according to Litvan et al. (2012) criteria,
specifically: (i) cognitive complaints corroborated by an assistant;
(ii) performance score at least 1.5 SD below the normative
population on two tests of a standardized neuropsychological
screening battery (see below for a detailed description of the
tests used). Exclusion criteria were: (i) the presence of major
psychiatric disorders, neurological conditions other than PD,
vascular brain lesions and major systemic or metabolic diseases
that could affect cognitive status as assessed by neuropsychiatric,
neuroradiological (CT or MR) and laboratory examinations;
(ii) taking medications (other than dopaminergic drugs) that
have an effect on brain functioning. According to Litvan et al.
(2012), PD patients were classified as havingMCI (single-domain
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MCI: N = 20 (F = 11; M = 9): 9 with amnestic and 11 with
dysexecutive profiles; multiple-domain MCI: N = 28 (F = 10;
M = 18): 19 with memory and executive impairments, 7 with
executive and visual-spatial impairments, 1 with memory and
visual-spatial impairments; 1 with memory, executive and visual-
spatial impairments), and patients without cognitive disorders
(PDN; N = 33; F = 15; M = 18). All PD patients were treated
with levodopa, dopamine agonists (pramipexole, ropinirole,
rotigotine) or monoamine oxidase inhibitor (rasagiline and
selegiline; in Table 1 average dopamine equivalent dosages are
reported for the three PD groups). The Unified PD Rating
scale Part-III (Fahn and Elton, 1987) was administered to assess
severity of extrapiramidal symptoms. The Activities of Daily
Living (ADL) and Instrumental Activities of Daily Living (IADL;
Lawton and Brody, 1969) and the Pill questionnaire (see below
for a detailed description of this tool; Dubois et al., 2007b)
were administered to assess patients’ ability to manage routine
activities.
Inclusion criteria for HC included: (i) absence of subjective
cognitive disturbances; (ii) MMSE score ≥26 (Measso et al.,
1991). Exclusion criteria were: (i) performance 1.5 SD below
the normative population on any test of the standardized
neuropsychological screening battery; (ii) presence of current or
previous neurological or psychiatric disorders, major systemic
or metabolic diseases able to induce significant changes in
cognition; and (iii) taking medications with an effect on brain
functioning.
Table 1 presents the socio-demographic and clinical
characteristics of the samples.
Neuropsychological Test Battery
Standardized tests were administered to PD patients to assess
episodic memory [Immediate and Delayed Recall of a 15-Word
List (Carlesimo et al., 1996); Prose Recall (Carlesimo et al., 2002);
Immediate and delayed reproduction of Rey’s Figure (Carlesimo
et al., 2002)], attention and short-term memory [Digit Span and
Corsi Block Tapping test Forward and Backward (Monaco et al.,
2013); the Trail Making Test—Part A (Giovagnoli et al., 1996)],
executive functions [Phonological Word Fluency (Carlesimo
et al., 1996); Modified Card Sorting test (MCST; Nocentini
et al., 2002); Raven’s Colored Progressive Matrices (Carlesimo
et al., 1996); the Trail Making Test—Part B (Giovagnoli et al.,
1996)], language [Objects and Verbs Naming subtests from
the Neuropsychological Examination of Aphasia (Capasso and
Miceli, 2001)], visual-spatial functions [Copy of Drawings and
Copy of Drawings with Landmarks (Carlesimo et al., 1996); Copy
of the Rey’s Figure (Carlesimo et al., 2002)].
Evaluation of PD Patients’ Ability to Self-Manage
Pharmacological Therapy
The Pill questionnaire (Dubois et al., 2007b) is an instrument
administered to patients and their caregivers that investigates
patients’ ability to manage their dopamine treatment. According
to the task force of the Movement Disorder Society, this
questionnaire assesses the impact of a decline in cognitive
functioning on daily living, taking into account the possible
effects of motor disorders. According to Dubois et al. (2007b) no
impact of cognitive disorders on daily living is present if a patient
is able to describe the drugs, doses and timing of therapy or in
cases in which the patient needs some help from the examiner but
the caregiver certifies that the patient can safely and reliably take
his/her pills without supervision (score = 4 and 3, respectively).
There is an impact on daily living if the caregiver reports that the
patient cannot take the pills without supervision or if the patient
is unable to describe (even with the help of the examiner) the
drugs, doses and timing of dopamine therapy (scores of 2 and 1,
respectively).
Assessment of Severity of (Depression) and
Apathy
The Beck Depression Inventory (Beck et al., 1961; Visser et al.,
2006) and the Apathy Evaluation Scale—Patient Version (Marin
TABLE 1 | Social-demographic and clinical characteristics of the four experimental groups.
Healthy PD patients without PD patients with F values p values
subjects N = 20 MCI N = 33 MCI N = 48
Age 66.0 (7.0) 63.4 (8.7) 66.0 (9.0) 1.02 0.37
Years of formal education 12.3 (3.6) 12.6 (3.0) 11.4 (4.3) 1.08 0.34
MMSE 29.4 (0.8)* 29.4 (0.8)** 28.5 (1.4) 8.13 0.001
BDI 6.5 (5.7) 8.7 (6.9) 8.7 (7.3) 0.65 0.52
AES 27.7 (4.6) 29.1 (8.9) 32.1 (6.9) 1.94 0.065
Pill questionnaire — 3.79 (0.54) 3.08 (1.05) 6.90 0.001
IADL — 7.4 (1.1) 6.8 (1.4) 1.76 0.074
Disease duration — 6.9 (4.7) 6.3 (4.1) 0.41 0.52
UPDRS—Part III (“on” condition) — 19.7 (13.5) 22.4 (11.7) 0.92 0.34
Levodopa equivalents — 607 (230) 616 (259) 0.03 0.87
*Indicates a significant difference between healthy subjects and PD individuals with MCI, with a p value ≤0.01 as results from LSD post hoc tests; ** Indicates a significant
difference between PD patients without MCI and the PD individuals with MCI with p < 0.01. SDMCI, single domain mild cognitive impairment; MDMCI, multiple domains
mild cognitive impairment; BDI, Beck Depression Inventory; AES, Apathy Evaluation Scale; IADL, Instrumental Activities of Daily Living; UPDRS, Unified Parkinson’s Disease
Rating Scale.
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et al., 1991; Leentjens et al., 2008) were also administered to assess
severity of depression and apathy, respectively.
The neuropsychological assessment and the administration of
self-report questionnaires was carried out on two different days
over a one-week period.
PM Task
Material
The material consisted of five different actions the subjects had
to perform at the expiration of the established time (i.e., open the
door, remember to turn on the computer, write their first and last
name on a sheet of paper, give a pen back to the examiner, setting
right the phone receiver). The examiner and the experimental
subject were seated on opposite sides of a table on which the
objects the subject had to use were located. A wall clock was
placed to the right of the subject so that he had to turn his head
to check it.
Procedure
The procedure is a slightly revised version of a task that was
previously used with individuals who hadMCI but not PD (Costa
et al., 2015b). It consists of five consecutive trials, which are
administered in approximately 50 min during administration
of the neuropsychological screening battery. First, a running
trial is performed. At the beginning of this trial the examiner
instructs the subjects (who are tested individually) to perform
the action after 2 min have elapsed. They have to repeat the
examiner’s instructions aloud. At the end of this trial the
examiner discusses the difficulties the subjects have encountered
in performing the task. After this trial, four other consecutive
trials are run. At the beginning of each trial, the examiner
instructs the subjects to perform an action after 10 min have
elapsed. Only this 10-min trials were considered to evaluate
performance. The subjects are informed that when the time
expires they will have up to 2 min to initiate the action (a
‘‘forgiveness period’’) and that they may then interrupt the
ongoing task. This delay was the same for all subjects. During
the delay interval the subjects are engaged in performing the
neuropsychological tests of the screening battery (Figure 1). In
particular, the sequence of events is programmed so as to avoid
synchrony between the moment when the prospective intention
has to be retrieved and the moment when the recall phase of the
episodic memory tests of the neuropsychological battery have
to be performed. If the subjects start to perform the required
actions within this time limit, the examiner records the action.
If the subjects do not engage in any action at the expiration
of the 2-min forgiveness period, the examiner reminds them:
‘‘Do you remember that at this point you were supposed to
do something?’’ If the response is affirmative, the examiner
records the action carried out. The same procedure is repeated
for all trials.
We computed one score for recalling the intention to perform
the actions (prospective component) and one for correctly
executing the actions (retrospective component). If the intention
was recalled, we gave a score of 1 for each spontaneously activated
intention and 0 if the intention was not recalled (score range
0–4). For action performance, regardless of whether or not the
FIGURE 1 | The Figure illustrates the order of administration of the
neuropsychological screening tests during the administration of the
prospective memory procedure.
intention was spontaneously recalled or had to be cued, we
assigned a score of 1 if the action was performed correctly, a score
of 0.5 if performance was partially correct and a score of 0 if the
action was completely incorrect or lacking (score range 0–4).
All PD patients were assessed approximately 60–90 min. after
they had received their dose of dopamine replacement drug.
Statistical Analysis
A general MANOVA and subsequent univariate ANOVAs were
performed to compare the three experimental groups on the
scores they obtained on the tests of the neuropsychological
screening battery. In the case of significant main effects post hoc
Tukey HSD were performed.
To compare PM performance between PD patients with MCI,
PD patients without MCI and HC subjects, a mixed ANOVA
was carried out with Group (PD patients with MCI vs. NPD
vs. HC) as between factor and Task Component (prospective
vs. retrospective) as within factor. In the case of significant
main effects, Tukey HSD post hoc tests were performed. To
investigate whether PD patients’ PM performance predicts Pill
questionnaire score, taking into account the weight of other
relevant factors, the forward linear regression model was applied.
The Pill score was entered in the model as dependent variable
and the prospective and retrospective component scores of
the PM task were entered as independent variables. According
to the rule of thumb, to maintain a ratio of 10 subjects for
each independent variable included in the regression model,
with a sample of 81 subjects a maximum of 8 independent
variables should be included. Therefore, we reduced the number
of the other possible covariates by selecting one measure for
each domain. Specifically, we included the UPDRS part-III
to assess severity of extrapiramidal symptoms, the AES for
apathy evaluation, the BDI as depression measure, the categories
achieved on the MCST as measures of executive functioning, the
delayed Prose Recall score as episodic memory measure and the
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MMSE score as an index of global cognitive functioning. The
regression analysis was executed in a first step on the whole
PD group and, in a second step, only with PD patients who
had MCI.
A mixed ANOVA was also performed to compare PM scores
between PD patients with single domain MCI who exhibit a
dysexecutive vs. amnesic cognitive profile.
Pearson’s correlation analyses were performed to examine the
relationship between PM scores and scores on the tests of the
neuropsychological screening battery that investigate episodic
memory and executive functions.
Results
Between Group Comparisons on the Tests of the
Neuropsychological Screening Battery
Results of the general MANOVA showed a significant effect
(Roy’s root (21,79) = 6.68; p< 0.001).
Results of univariate comparisons are reported in detail in
Table 2. To summarize these results, a significant between groups
effect with p < 0.05 was found for all tests included in the
analysis, with the exception of the Digit Span Forward and
Backward, the Corsi Block Tapping test Forward and Prose
Memory Immediate Recall. Post hoc Tukey HSD comparisons
showed that PD patients with MCI had significant lower
scores on HC on all tests (all p consistently <0.05) with the
exception of Prose Memory Delayed Recall (p = 0.06) and verbs
(p = 0.09) naming and Corsi Block Tapping test Backward
(p = 0.18). Moreover, PD patients with MCI had significant
poorer performance than PDN on all tests (all p consistently
<0.05). Post hoc comparisons between HC and PDN groups did
not reveal any significant effect (p range: 1–0.09).
Between Group Comparisons of PM
Performance
Figure 2 illustrates performance of the four experimental groups
on the PM procedure.
Results of the mixed ANOVA show a main effect
of the Group (F(2,98) = 4.32; p = 0.016) and Task
Component (F(1,98) = 5.99; p = 0.016) factors. By contrast, the
interaction between the two main factors did not reach statistical
significance (F(1,98) = 0.79; p = 0.45). The main effect of the Task
Component documents that in the whole sample the prospective
component score was significantly lower than the retrospective
component score (mean = 3.07; SD = 0.99 and mean = 3.36;
SD = 0.82, respectively). Tukey HSD tests made to qualify the
Group effect documented that, independently from the PM
task component considered, PD patients with MCI (prospective
component: mean = 2.85; SD = 1.05; retrospective component:
mean = 3.14; SD = 1.01) performed worse than HC (prospective
component: mean = 3.45; SD = 0.89; retrospective component:
mean = 3.53; SD = 0.52; p = 0.034; Cohen’s d = 0.57) and
tended to perform worse than PDN individuals (prospective
component: mean = 3.15; SD = 0.91; retrospective component:
TABLE 2 | Average scores obtained by subjects of the three experimental groups with results of univariate ANOVAs are reported.
Neuropsychological PD patients PD patients Healthy controls p values
screening battery with MCI with MCI controls
Mean (SD)
Episodic Memory
15-Rey’s Word List—Immediate Recall 29.8(9.1) 41.4 (7.3) 46.0 (9.0) <0.001
15-Rey’s Word List—Delayed Recall 5.8 (2.4) 9.0 (2.2) 9.7 (2.3) <0.001
Rey’s Figure—Immediate Recall 10.0 (6.3) 16.7 (6.8) 17.0 (7.1) <0.001
Rey’s Figure—Delayed Recall 9.2 (5.9) 16.4 (9.2) 16.4 (6.1) <0.001
Prose Memory—Immediate Recall 5.1 (1.5) 5.5 (1.4) 5.9 (1.2) 0.097
Prose Memory—Delayed Recall 4.8 (1.6) 5.6 (1.4) 5.7 (1.1) 0.016
Attention and Short-term Memory
Trail Making Test—Part A 66.5 (27.6) 46.4 (14.8) 37.2 (13.9) <0.001
Digit Span Forward 5.5 (1.1) 5.9 (1.0) 5.9 (0.8) 0.11
Corsi Block Tapping test Forward 4.7 (0.9) 5.1 (0.8) 4.9 (0.8) 0.13
Digit Span Backward 3.8 (1.5) 4.3 (0.9) 4.2 (0.7) 0.12
Corsi Block Tapping test Backward 4.1 (1.0) 4.7 (0.8) 4.6 (0.7) 0.022
Executive Functions
Modified Card Sorting Test—Categories Achieved 3.9 (1.9) 5.7 (0.5) 5.7 (0.7) <0.001
Modified Card Sorting Test—Perseverative Errors 5.2 (5.2) 2.1 (2.0) 2.0 (2.3) 0.001
Trail Making Test—Part B 227.8 (105.3) 131.2 (46.9) 102.1 (36.6) <0.001
Raven’s Colored Progressive Matrices 25.6 (4.5) 30.4 (3.9) 30.4 (4.5) <0.001
Phonological Verbal Fluency 25.6 (9.9) 35.6 (9.5) 35.7 (5.4) <0.001
Language
Objects Naming 28.6 (3.1) 29.8 (0.5) 29.8 (0.6) 0.019
Verbs Naming 26.1 (3.2) 27.5 (0.9) 27.4 (0.8) 0.013
Visual-spatial Functions
Rey’s Figure—Copy 27.2 (5.5) 30.4 (4.3) 32.4 (2.6) <0.001
Copy of Drawing 8.6 (1.5) 9.8 (1.3) 10.4 (1.3) <0.001
Copy of Drawing with Landmarks 66.9 (3.7) 68.7 (2.1) 68.9 (1.7) 0.009
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FIGURE 2 | The Figure illustrates the average performance accuracy of
the individuals of the three experimental groups on the prospective
and retrospective component of the prospective memory (PM)
procedure. Vertical bars represent standard errors.
mean = 3.59; SD = 0.55; p = 0.064; Cohen’s d = 0.43). The
comparison between PDN and HC groups showed, instead, that
the result was quite far from the statistical significance (p = 0.84;
Cohen’s d = 0.17).
Factors Predicting the Pill Questionnaire Score
Regressions Performed on the Whole PD Group
In the first step of this analysis the MCST-categories score
entered the regression equation (F(1,80) = 19.7; p < 0.001;
R2 = 0.20) with a positive correlation with the dependent
variable (Beta = 0.45; Pearson’s r = 0.45; t = 4.44; p < 0.001).
This shows that better performance on this test is associated
with better self-management of pharmacological therapy.
In the second step the prospective component score of the
PM procedure significantly contributed to the model (R2
change = 0.074; F(2,80) = 14.8; p < 0.001), also in this
case it correlated positively with the criterion (Beta = 0.27;
Pearson’s r = 0.30; t = 2.83; p = 0.006), thus documenting
that better intention retrieval is associated with better scores
on the Pill questionnaire. The last variable entering the
regression equation was, in the third step, the AES score (R2
change = 0.041; F(3,80) = 11.91; p < 0.001); in this case it
correlated inversely with the dependent variable (Beta = −0.21;
Pearson’s r = −0.27; t = −2.19; p = 0.032). This documents
that lower apathy rates are associated with better Pill
questionnaire scores. None of the other factors tested
contributed significantly to the model (partial correlations:
retrospective component of the PM task = −0.05; UPDRS
part-III = −0.05; BDI = 0.11; delayed Prose Recall = −0.01;
MMSE = 0.05).
Regressions Performed Selectively on the MCI
Sample
These regressions were executed to verify the above findings
in the MCI group. The dependent variable was the same as
above (i.e., score on the Pill questionnaire). In this case, however,
the independent variables were those for which a significant
effect had been found in the previous analysis, that is, the
categories achieved on theMCST, the AES score and accuracy on
the prospective component of the PM task. Results substantially
confirmed the findings on the whole PD sample, with the
exception of the AES, which no longer approached statistical
FIGURE 3 | The Figure illustrates, in the PD patients with MCI, the
correlation between the score on the Pill questionnaire and accuracy
score on the prospective component of the prospective memory
procedure.
significance (Beta = −0.21; t = −1.61; p = 0.12). In particular, in
the first step the MCST-categories score (F(1,46) = 6.87; p = 0.012;
R2 = 0.13), and in the second step the prospective component
score of the PM task (F(1,45) = 6.89; p = 0.002; R2 = 0.23;
Figure 3) significantly entered the regression equation. Also
in these cases the two explicative factors correlated positively
with the dependent variable (with Beta = 0.36; and Beta = 0.32,
respectively).
Relationship Between PM and Executive
Functioning in the MCI Sample
Comparisons Between PD Patients with Executive
and Amnestic Cognitive Profile within the Single
Domain MCI Group
Results of the mixed ANOVA do not show any significant
effect (Group: F(1,18) = 0.07; p = 0.79; Task Component:
F(1,18) = 2.97; p = 0.10; Group∗Task Component
interaction (F(1,18) = 0.97).
Correlation Between Scores on Tests of the
Neuropsychological Screening Battery that
Investigate Episodic Memory and Executive
Functions and PM Scores
The following tests were considered for episodic memory:
Delayed Recall of a 15-Word List and Prose Memory Delayed
Recall. The following tests were taken into account for the
executive domain: Phonological Word Fluency, MCST (both
categories achieved and perseverative errors) and the Trail
Making Test (Part B—Part A). Correlation analyses were
performed separately for the prospective and retrospective
component of the PM task. In order to avoid the risk of
alpha inflation, Bonferroni’s correction was applied to these
analyses. Accordingly, with six correlations the p value for
considering a correlation as significant was set at 0.008 (i.e.,
p = 0.05/6).
Results of the correlation analyses did not reveal any
significant effect both for the prospective component (r ranged
from −0.09 to 0.12, and p ranged from 0.83 to 0.40) and the
retrospective component (r ranged from 0.06 to 0.34 and p
ranged from 0.81 to 0.018).
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Discussion
This study was aimed at investigating time-based PM functioning
and its relationship with autonomous management of
medication in PD patients with and without MCI. The first
main finding of the study is that PD patients with MCI
performed significantly worse than HC on both the prospective
and retrospective components of a time-based PM procedure.
Moreover, with respect to the PDN group (i.e., PD patients
who showed no significant cognitive impairment on a standard
neuropsychological examination), the MCI group tended to
perform worse on the PM task. By contrast, no significant
PM performance difference was found between PDN and
HC groups. It is unlikely that the above differences between
the PD sub-groups were due to the clinical characteristics of
the samples, as patients in the various PD subgroups were
comparable for duration and severity of the disease and
dopamine dosage.
To the best of our knowledge, this is the first study that
has investigated time-based PM abilities in PD patients with
MCI. Therefore, the results add new valuable information to
the extant literature because they document that in PD patients
time-based PM weakness is related to the presence of MCI.
Indeed, previous studies examined time-based PM functioning
in PD patients and demonstrated that their performance was
significantly poorer than that of healthy controls (Costa et al.,
2008b; Raskin et al., 2011; but see Katai et al., 2003 for
partially divergent results). In those studies, however, the
possible effect of MCI was not investigated. Very interestingly,
our findings are substantially in line with the results of a
previous study in which event-based PM performance was
found to be significantly decreased in PD patients with MCI
compared to PD patients without cognitive impairments who,
in turn, performed as well as healthy controls (Costa et al.,
2015a). Taken together the current and previous findings
provide convergent evidence of a strict association between
PM deficits and MCI in PD patients, thus investigating PM
functioning might help significantly in discriminating between
MCI and non-MCI in PD. From a clinical perspective, this
is a very important observation. In fact, the presence of MCI
is associated with increased risk of dementia in the affected
individual (Janvin et al., 2006; Litvan et al., 2012). Therefore,
the early identification of MCI in PD should be a main goal to
improve management and treatment of the disease (Emre et al.,
2014).
However, it should be noted that we did not find a
clear dissociation between the prospective and retrospective
component of the PM task. Indeed, PD patients with MCI
appear to be equally impaired in both PM components.
Previous studies showed that PD patients, compared with both
healthy controls and PD patients without MCI, have reduced
performance on traditional episodic memory tests (Emre et al.,
2007). Two main hypotheses have been advanced to account
for such an evidence. The first hypothesis sees memory
disorders in these patients as a consequence of consolidation
failure. This hypothesis is grounded on findings showing that
individuals with PD have lower performance than healthy
controls in recognition and semantic cued recall tasks (Higginson
et al., 2005; Davidson et al., 2006; Cohn et al., 2010). The
second hypothesis views memory weakness as a consequence
of encoding or retrieval failures. Data evidencing that PD
patients significantly benefit by a semantic cueing of studied
information and that their performance significantly improves in
recognition tests sustain this hypothesis (Dujardin and Laurent,
2003; Emre et al., 2007). The pattern of memory disorders
in PD patients with MCI is, indeed, poorly investigated. In
a previous study we documented that PD patients with MCI,
compared to non PD amnestic MCI individuals, significantly
improved their memory recall in the Free and Cued Selective
Reminding test after the semantic cue presentation (Costa
et al., 2014). This finding could support the hypothesis that,
in these individuals, memory disorders are mainly related to
retrieval failure, likely as a consequence of reduced efficiency
of frontal-striatal networks (Cools, 2006). However, in the
current study, we did not find a clear relationship between PM
performance and scores on the executive tests (and episodic
memory tests) of the neuropsychological battery. Moreover,
we did not find a clear difference on the PM performance
pattern between PD patients with disexecutive and amnestic
neuropsychological profile. This null finding could be due
to the relatively low sample size of the single-domain MCI
groups (n = 11 and n = 9, respectively). This issue is undoubtedly
worth of further investigation in larger samples of PD patients
with MCI.
The second main finding of this study also shows that
PM assessment can provide some relevant information about
patients’ functional autonomy. We applied a linear regression
model to the data to investigate whether PM performance
predicts PD patients’ ability to manage their own medication;
we also took into account the potential effect of other cognitive,
affective and motor factors. We entered the Pill questionnaire
score as the dependent variable. The Task Force of theMovement
Disorder Society (Dubois et al., 2007b) recommends that this
tool be used to assess the impact of cognitive impairments on
functional abilities in the PD population. It is held that the Pill
questionnaire overcomes the limits of other instruments (e.g.,
ADL and IADL), which can be affected by PD-related motor
symptoms (Dubois et al., 2007b). We found that the best model
for predicting the Pill questionnaire score included accuracy on
the prospective component of the PM task, number of categories
achieved on theMCST and AES score. When the PDN group was
excluded from the analysis (and only the MCI sample remained),
the PM prospective component and the MCST scores remained
significant predictors and the AES score effect was no longer
significant. The relationship between the explicative variables
and the criterion was in the expected direction, that is, better
scores on the former were associated with better scores on
the latter.
Our finding of a significant association between PM
performance and PD patients’ autonomous management of their
own medication was expected. Indeed, taking prescribed drugs
at the correct time depends on the ability to monitor the time
course and to spontaneously retrieve the related intention by
interrupting the ongoing activity. This condition is quite similar
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to that represented by our PM procedure. In this regard, it
is noteworthy that accuracy on the prospective (but not on
the retrospective) component predicted the Pill questionnaire
score. In fact, the prospective component of our procedure was
completely self-guided as it specifically required that subjects
autonomously shift their attention from the ongoing task to
performing the planned action in the right time window
without any explicit prompting by the examiner. Instead, the
retrospective component required less self-management of the
task. In fact, if the subject did not autonomously begin to
perform the action (i.e., prospective component score = 0), he
was reminded by the examiner that he was expected to perform
some actions at the expiration of the 10-min period.
Our result was also expected on the basis of previous data
suggesting that in PD patients there is a relationship between
PM functioning and functional abilities (Pirogovsky et al.,
2012; Costa et al., 2015a). However, with respect to previous
findings the current result clarifies that this association is
significant in PD patients with MCI independently from the
effect of other cognitive (i.e., executive and episodic memory),
affective (depression and apathy) and motor symptoms. In this
regard, the finding that PM accuracy entered the regression
model together with the MCST score, significantly improving
the amount of variance explained by the model itself, is
of particular interest. Indeed, it is generally held that the
prospective component of a PM task, such as the one used
here, depends strictly on the correct functioning of the executive
system (Costa et al., 2011a; McDaniel and Einstein, 2011).
Strategic monitoring of the time passing and shifting from the
ongoing activity to intention retrieval are particularly stressed.
Coherently, data obtained from healthy subjects (Burgess et al.,
2011; Costa et al., 2011b, 2013b; Cona et al., 2015) and
neurological patients (Kinsella et al., 1996; Fish et al., 2010;
Carlesimo et al., 2014) document that the ability to spontaneously
retrieve the intention during a PM task is associated with
prefrontal cortex activity. However, as discussed above, the PM
procedure resembles a multitasking condition in that it requires
that subjects keep in memory and autonomously retrieve the
intention to perform an action while performing an intercurrent
ongoing activity. This condition seems substantially different
from that proposed in the MCST and other classical executive
tests and is probably more akin to daily living functioning.
As a matter of fact we did not find significant correlations
between scores on the executive tests of the neuropsychological
screening battery and PM scores. Based on this observation, we
can conclude that the additional amount of variance explained
by the regression model by entering the PM score is related to
this own characteristic of the PM procedure. In agreement with
results of previous research (Pirogovsky et al., 2012; Costa et al.,
2015a), this conclusion supports the ecological validity of PM
tasks.
In conclusion, the results of this study demonstrate that in
PD patients time-based PM weakness is specifically related to
the presence of MCI. This finding indicates the importance
of PM assessment to identify MCI during the course of
PD. In this regard, it should be noted that in the current
study we administered a PM task that was incorporated
in the standard neuropsychological battery. This means that
this task has the great advantage of not requiring significant
additional time to assess PM. The same data indicate that
the decreased efficiency of the time-based PM processes is
associated with reduced independent behavior. Indeed, in PD
patients dopamine therapy is often very complex and requires
that doses be taken at different times of the day. Missing
or repeatedly delaying medication may lead to a significant
worsening of the patient’s condition. This observation further
strengthens the potential importance of planning training
programs aimed at improving PM abilities in PD patients
with MCI.
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